Tech Company Financing Transactions
Enzyre Funding Round
Oost NL, Demcon Investment and i&i Biotech Fund participated in a $11.7 million Series A funding round for Enzyre. This venture round was announced on 11/3/2022.
Transaction Overview
Company Name
Announced On
11/3/2022
Transaction Type
Venture Equity
Amount
$11,690,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Enzyre BV Transistorweg 5
Nijmegen, 6534-AT
NL
Nijmegen, 6534-AT
NL
Phone
Website
Email Address
Overview
Enzyre's mission is to save patients from bleeding to death. Our Enzypad technology fulfils that mission anywhere in the world.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guido Maertens
Chief Operating Officer
Ivo Aarninkhof
Chief Scientific Officer
Waander Heerde
Browse more venture capital transactions:
Prev: 11/3/2022: apiiro venture capital transaction
Next: 11/3/2022: FLX Networks venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs